Menu Search
Equities

Vitrolife AB

VITR:STO

Vitrolife AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)216.80
  • Today's Change4.00 / 1.88%
  • Shares traded7.61k
  • 1 Year change+19.12%
  • Beta2.1273
Data delayed at least 15 minutes, as of Nov 22 2024 10:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in SEK

The 4 analysts offering 12 month price targets for Vitrolife AB have a median target of 270.00, with a high estimate of 280.00 and a low estimate of 250.00. The median estimate represents a 26.88% increase from the last price of 212.80.
High31.6%280.00
Med26.9%270.00
Low17.5%250.00

Dividends in SEK

In 2023, Vitrolife AB reported a dividend of 1.00 SEK, which represents a 17.65% increase over last year. The 3 analysts covering the company expect dividends of 1.18 SEK for the upcoming fiscal year, an increase of 17.70%.
Div growth (TTM)17.65%
More ▼

Earnings history & estimates in SEK

On Oct 24, 2024, Vitrolife AB reported 3rd quarter 2024 earnings of 0.85 per share.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate-0.18%
Vitrolife AB reported annual 2023 earnings of 3.31 per share on Feb 02, 2024.
Average growth rate-0.25%
More ▼

Revenue history & estimates in SEK

Vitrolife AB (publ) had 3rd quarter 2024 revenues of 867.00m. This missed the 902.52m consensus estimate of the 5 analysts following the company. This was 1.52% above the prior year's 3rd quarter results.
Average growth rate+0.92%
Vitrolife AB (publ) had revenues for the full year 2023 of 3.51bn. This was 8.60% above the prior year's results.
Average growth rate+30.02%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.